Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) in China to initiate a clinical study for its programmed death-1 (PD-1) inhibitor, BAT1308, in the treatment of endometrial cancer. BAT1308 is an internally developed PD-1 monoclonal antibody (mAb) designed to bind to PD-1 on the surface of T cells, alleviating the immune inhibitory effect of the PD-1 pathway and thereby enhancing T cell immune response against tumors.
Previously, BAT1308 had been approved for clinical studies in combination with platinum chemotherapy with/out bevacizumab for cervical cancer and in combination with BAT4706, Bio-Thera’s cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, for advanced solid tumors.- Flcube.com
